Oncology artificial intelligence (AI) company Vysioneer has announced a strategic collaboration with Mitsubishi Corporation subsidiary MC Medical to introduce a new brain tumour auto contouring AI solution to the Japanese market.
This technology, named VBrain, is designed to improve clinical workflows and treatment accuracy for brain radiosurgery and radiotherapy, which are said to be crucial for patients with brain metastases.
Go deeper with GlobalData
In Japan, 20–40% of cancer patients develop secondary brain tumours, known as brain metastases.
VBrain aims to address this challenge by significantly reducing the workload of medical professionals while simultaneously improving patient care quality.
VysioneerCEO Dr Jen-Tang Lu said: “Japan stands at the forefront of advanced radiotherapy technology, and we are deeply honored to introduce our cutting-edge AI solution in this pioneering nation.
“Through our collaboration with MC Medical, we will empower healthcare professionals and elevate patient outcomes together.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDuring the collaboration, Vysioneer engaged with three hospitals in Japan, where the AI solution received positive feedback from key opinion leaders in brain tumour management.
MC Medical president and CEO Shinya Taniguchi said: “We are excited about cutting-edge software sales. It has the potential to significantly reduce work time in the field of radiation surgery planning and therapy planning. We are confident that this is a product that will revolutionise.”
Said to be the first-ever tumour auto-contouring system, VBrain holds the potential to optimise brain tumor radiosurgery with improved efficiency.
Through partnerships with Stanford Cancer Institute, Pfizer and GE Healthcare, Vysioneer’s AI solutions have been used in cancer centres as well as pharma clinical development.
